Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. (Q35012871)

5 August 2017

Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]. (English)

1 reference

5 August 2017

1 reference

Vasso Apostolopoulos

1

0 references

Magdalena Plebanski

8

object named as

Magdalena Plebanski

1 reference

5 August 2017

Geoffrey A Pietersz

2

1 reference

5 August 2017

Anastasios Tsibanis

3

1 reference

5 August 2017

Annivas Tsikkinis

4

1 reference

5 August 2017

Heleni Drakaki

5

1 reference

5 August 2017

Bruce E Loveland

6

1 reference

5 August 2017

Sara J Piddlesden

7

1 reference

5 August 2017

Dodie S Pouniotis

9

1 reference

5 August 2017

Michael N Alexis

10

1 reference

5 August 2017

Ian F McKenzie

11

1 reference

5 August 2017

Stamatis Vassilaros

12

1 reference

5 August 2017

15 June 2006

1 reference

5 August 2017

Breast Cancer Research

1 reference

5 August 2017

8

1 reference

5 August 2017

3

1 reference

5 August 2017

R27

1 reference

https://scigraph.springernature.com/pub.10.1186/bcr1505

5 August 2017

0 references

cites work

Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: a new approach for vaccine design

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Role of the mannose receptor in the immune response

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

8 July 2018

MUC1 and breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Generation of MUC1 cytotoxic T-cells in mice and epitope mapping

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Generation of cellular immune responses to antigenic tumor peptides

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

MUC1 peptide epitopes associated with five different H-2 class I molecules

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Human B-cell immune response to the polymorphic epithelial mucin.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1.

8 July 2018

1 reference

Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection

21 January 2018

1 reference

Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer

21 January 2018

1 reference

Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

21 January 2018

1 reference

Phase-I study of synthetic muc1 peptides in breast-cancer.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1557739

Cell-mediated immune responses to MUC1 fusion protein coupled to mannan

25 October 2018

1 reference

Cytokine Production from Murine CD4 and CD8 Cells After Mannan-MUC1 Immunization

21 January 2018

1 reference

Parameters for using mannan-MUC1 fusion protein to induce cellular immunity

21 January 2018

1 reference

The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A

21 January 2018

1 reference

12 December 2020

CTL in mice immunized with human mucin 1 are MHC-restricted

1 reference

12 December 2020

Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours

1 reference

12 December 2020

Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice

1 reference

12 December 2020

Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin

1 reference

12 December 2020

Monoclonal antibodies reactive with mucin expressed in breast cancer

1 reference

12 December 2020

Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients

1 reference

12 December 2020

Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides

1 reference

12 December 2020

Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy

1 reference

12 December 2020

MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines

1 reference

12 December 2020

In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors

1 reference

12 December 2020

Aldehyde-mannan antigen complexes target the MHC class I antigen-presentation pathway

1 reference

12 December 2020

Evaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells

1 reference

12 December 2020

The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan-MUC1

1 reference

12 December 2020

Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP)

1 reference

12 December 2020

Identifiers

DOI

10.1186/BCR1505

1 reference

Dimensions Publication ID

5 August 2017

0 references

1 reference

5 August 2017

1 reference